Source: Finance DW, extracted 31 Aug 2026. September excluded as an open period.
The pattern
The decline is steady, not a single bad month
SouthernGroup average
Contribution margin, %, closed periods only.
Diagnosis
We cannot yet separate price from mix
Volume is down 9.4%
Consistent across all four depots, so not a local failure.
Realised price is down 3.1%
Concentrated in two contracts renewed in March.
Whether mix explains the rest
The route-level cost feed has not delivered since July.
This is the gap the diagnostic closes.
We are missing route-level cost.
Any margin-bridge we build today would be an estimate presented as a fact.
Options
Three paths, with what each one costs to be wrong
Option
In-quarter cost
If we are right
If we are wrong
Fund recovery now
€1.8m
Region stabilises by Q1
€1.8m into a structural decline
Reallocate to North and Central
€0.3m
Contribution up ~€0.6m
Exit a market we could have kept
Diagnose first, decide in November
€0.1m
Decision made on evidence
Six weeks of continued bleed (~€0.2m)
Costs are directly attributable only; no overhead allocation.
Recommendation
Diagnose first — the option value exceeds the carry cost
Six weeks of bleed costs roughly €0.2m. Choosing wrong between the other
two options costs between €0.6m and €1.8m. The diagnostic is cheap relative
to the decision it informs.
NowFreeze discretionary spend
OctRoute diagnostic
NovDecision point
DecExecute
What would change our minds
If October volume falls below 82k shipments, we reallocate without waiting
That threshold is where the recovery case stops clearing its own cost of
capital on any reasonable price assumption. It is measurable on 3 November.
Stating the falsifier in advance is what separates
a recommendation from a preference.